Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
317.50    0.50 (0.16%)
Bid:
315.50
Ask:
317.00
Spread: 1.50 (0.475%)
Market Cap: £732.37m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

Director/PDMR Shareholding

26 Nov 2021 13:00

RNS Number : 7435T
Chesnara PLC
26 November 2021
 

CHESNARA plc

("Chesnara" or "the Company")

 

26 November 2021

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS / PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY ('PDMRs')

 

Further to the appointment of Steve Murray as Group Chief Executive on 19 October 2021, Chesnara plc (the 'Company') today announces that, under the terms of his appointment, Steve (a PDMR) was granted awards in the ordinary shares of the Company under the Chesnara plc 2014 Long-Term Incentive Scheme to compensate him for remuneration arrangements forfeited on leaving his former employer, The Royal London Mutual Insurance Society Limited. These awards were made in accordance with the Company's Directors' Remuneration Policy and are subject to the Executive Directors' Minimum Shareholding Policy.

 

The notification below, which is being made in accordance with the requirements of Article-19 of the EU Market Abuse Regulation 596/2014 as retained in UK law by virtue of the European Union (Withdrawal) Act 2018, provides further detail of the awards granted.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

b)

Natural person:

Legal person

Steven Grant Murray

2

Reason for the notification

a)

Position/status:

Executive Director and Group Chief Executive

b)

Initial notification/amendment

Initial notification

3

Details of the Issuer

a)

Name

Chesnara plc

b)

Legal Entity Identifier:

213800VFRMBRTSZ3SJ06

4

Details of the transaction(s): Parts a-d of this section are to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument, type of instrument (Identification code)

Chesnara plc Ordinary Shares of 5 pence each

(GB00B00FPT80)

b)

Nature of the transaction

GRANT 1

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2021.

 

Subject to the achievement of the performance target, the option will become exercisable on 31 December 2021 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 2

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2021.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2022 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 3

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2022.

 

Subject to the achievement of the performance target, the option will become exercisable on 31 December 2022 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

GRANT 4

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2022.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 April 2023 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 5

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 30 June 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2023 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 6

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 April 2024 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 7

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2024 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

GRANT 1

50,456 Ordinary shares of 5p each

Nil

GRANT 2

119,089 Ordinary shares of 5p each

Nil

GRANT 3

50,456 Ordinary shares of 5p each

Nil

GRANT 4

119,089 Ordinary shares of 5p each

Nil

GRANT 5

20,722 Ordinary shares of 5p each

Nil

GRANT 6

140,105 Ordinary shares of 5p each

Nil

GRANT 7

33,625 Ordinary shares of 5p each

d)

Aggregated information

- Aggregated volume

- Price

 

- 533,542 ORDINARY SHARES OF 5P EACH

- Nil

e)

Date of the transaction (YYYY - MM - DD)

2021-11-26

f)

Place of the transaction

XOFF

 

 

Name of authorised official of issuer responsible for making notification: - Al Lonie

 

Date of notification: - 26 November 2021

 

For further information, please contact:

 

Roddy Watt

Director, Capital Markets

FWD

Forward thinking communications

 

T - 020 7280 0651

E - roddy.watt@fwdconsulting.co.uk 

 

 

Notes to Editors

Chesnara is a life and pensions company listed on the London Stock Exchange. It administers approximately 900,000 policies and operates as Countrywide Assured in the UK, as The Waard Group and Scildon in the Netherlands, and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 17 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPGBPGUPGGUQ
Date   Source Headline
8th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSDirectorate Change
29th Nov 202312:00 pmRNSHolding(s) in Company
21st Nov 202312:55 pmEQSHardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
17th Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 202312:00 pmRNSDirector/PDMR Shareholding
15th Nov 20237:00 amRNSUpdate on AGM Voting
25th Oct 20237:00 amRNSBlock listing Interim Review
25th Oct 20237:00 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSDirector/PDMR Shareholding
20th Oct 202310:30 amEQSHardman & Co Analyst Interview on Chesnara plc (CSN): A robust approach to cash generation
4th Oct 20233:30 pmEQSHardman & Co Research: Chesnara plc (CSN) - Good first half aided by markets and acquisitions
21st Sep 20237:00 amRNSHalf-year Report
1st Sep 20237:00 amRNSNotice of Half Year Results
31st Jul 20237:00 amRNSTotal Voting Rights
17th Jul 20237:00 amRNSAppointment of Joint Corporate Broker
11th Jul 202311:45 amRNSDirector/PDMR Shareholding
7th Jul 20237:00 amRNSDirector/PDMR Shareholding
29th Jun 20239:15 amRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmEQSCORRECTION Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
6th Jun 202310:30 amEQSHardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
2nd Jun 20232:10 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSTotal Voting Rights
23rd May 20231:05 pmEQSHardman & Co Research on Chesnara plc (CSN): Nice little acquisition
22nd May 20237:00 amRNSNew strategic partnership for Chesnara Plc
19th May 20237:00 amRNSDirector/PDMR Shareholding
16th May 20232:24 pmRNSResult of AGM
16th May 20237:00 amRNSAcquisition
4th May 20232:30 pmEQSHardman & Co Q&A on Chesnara plc (CSN): Strong cash generation through tough markets
28th Apr 20237:00 amRNSTotal Voting Rights
25th Apr 20237:00 amRNSBlock listing Interim Review
21st Apr 202312:27 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSNotice of AGM
11th Apr 20238:05 amEQSHardman & Co Research on Chesnara plc (CSN): Great cash flow in tough markets
31st Mar 20237:00 amRNSTotal Voting Rights
30th Mar 20237:00 amRNSFinal Results
1st Mar 20237:00 amRNSNotice of Results
28th Feb 20237:00 amRNSTotal Voting Rights
17th Feb 20237:00 amRNSHolding(s) in Company
31st Jan 20237:00 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSTotal Voting Rights
19th Dec 20227:00 amRNSHolding(s) in Company
16th Dec 20227:00 amRNSAcquisition
30th Nov 20227:00 amRNSTotal Voting Rights
15th Nov 20227:00 amRNSHolding(s) in Company
14th Nov 20227:00 amRNSDirector/PDMR Shareholding
11th Nov 20227:00 amRNSDirector/PDMR Shareholding
1st Nov 202212:15 pmRNSDirector/PDMR Shareholding
31st Oct 20227:00 amRNSTotal Voting Rights
27th Oct 20222:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.